Edmolin.com

Informed Today Influential Tomorrow

Medicine

Brenntag Specialties becomes global strategic distributor for K+S

Brenntag has announced a new strategic partnership with K+S Minerals and Agriculture – a globally oriented raw materials company – for the worldwide distribution of three pharmaceutical salts.

K+S is one of the world’s largest producers of pharmaceutical salts and produces its high-purity Sodium Chloride and Potassium Chloride at several European sites. Brenntag will now distribute three of their salts in the pharmaceutical market: APISAL Sodium Chloride GMP grade (in pharmacopoeia quality, API), Potassium Chloride 99.9 % KCl Ph. Eur., USP (API) and HD-NaCl (excipient grade). The salts are manufactured using special processes to ensure purity and meeting the strict quality requirements of the pharmacopoeias (European Pharmacopoeia, US Pharmacopeia). Examples for final dosage forms are hemodialysis, infusion and injection solutions, electrolyte preparations and tablets. 

“By adding K+S’ pharmaceutical salts, such as Sodium and Potassium Chloride, to our portfolio, we are strengthening our role as a key supplier to the global healthcare industry. Our commitment to providing these important ingredients ensures that our customers worldwide have access to the highest quality components needed to produce effective pharmaceuticals, electrolyte therapies and dietary supplements. With this partnership, we combine decades of experience, because not only we at Brenntag are celebrating our 150th anniversary this year, K+S is also celebrating an important milestone: 135 years of company history,” commented Torsten Walz, global president Brenntag Specialties Pharma.

“Partnering with Brenntag globally is one of our next strategic milestones. We will extend our market presence as one of the leading pharmaceutical salts producers in the world. We will continue our mission to further develop our specialty business. We stand for quality and reliability. K+S therefore contributes to a secure pharmaceutical salt supply and thus brings value, health, and growth to our customers and their patients.”, adds Holger Bekemeier, senior vice president of K+S’ Customer Segment Industry+.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *

Medicine

GSK’s RSV Vaccine Accepted Under Priority Review in USGSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted under priority review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease. If approved, GSK’s RSV vaccine would be the first vaccine available to help protect this population. Arexvy is currently approved in the US in adults aged 60 and over for the prevention of lower respiratory tract disease (LRTD) caused by RSV. The application is supported by positive results from a phase III trial [NCT05590403]4 evaluating the immune response and safety of GSK’s RSV vaccine in adults aged 50-59, including those at increased risk for RSV-LRTD due to underlying medical conditions. GSK used a Priority Review Voucher to reduce the US FDA review period of a supplemental Biologics License Application (sBLA) by four months. The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is 7 June 2024. The burden of RSV disease in adults is likely to be underestimated due to lack of awareness, a lack of standardised testing, and under-detection in surveillance studies.5 People with underlying medical conditions, such as chronic obstructive pulmonary disease (COPD), asthma, chronic heart failure6 and diabetes,7 are at increased risk for RSV disease. RSV can exacerbate these conditions and lead to pneumonia, hospitalisation, or death.8